Clinical Trial Update: Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

A multi-center, open-label Phase 2 trial evaluating the efficacy and safety of donor-derived CD7 CAR T cells in relapsed or refractory T-cell leukemia/lymphoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Leukemia
• T-cell Lymphoma
• T-lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Donor-Derived CD7 CAR T Cells (CD7 CAR T cells)

Snippet

Sponsor: Beijing Boren Hospital | Conditions: T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Status: COMPLETED